Jan Spanholtz
Chief Tech/Sci/R&D Officer at Glycostem Therapeutics BV
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Jan C. M. van der Hoeven | M | - |
Glycostem Therapeutics BV
Glycostem Therapeutics BV BiotechnologyHealth Technology Glycostem Therapeutics BV operates as a life science company which develops cellular immunotherapy and production technology platforms. It develops cellular immunotherapeutic for the treatment of leukemia, lymphomas, and other forms of cancer. The firm provides Prototype NK-cell and NK-cell progenitor cell products for clinical evaluations and intervention studies; and GBGM, a cell survival and minimal cellular delineation in expansion and differentiation experiments. The company was founded by Dirk Groenewegen and Jan van der Hoeven in 2007 and is headquartered in Oss, the Netherlands. | - |
Wim Jongen | M | - |
Glycostem Therapeutics BV
Glycostem Therapeutics BV BiotechnologyHealth Technology Glycostem Therapeutics BV operates as a life science company which develops cellular immunotherapy and production technology platforms. It develops cellular immunotherapeutic for the treatment of leukemia, lymphomas, and other forms of cancer. The firm provides Prototype NK-cell and NK-cell progenitor cell products for clinical evaluations and intervention studies; and GBGM, a cell survival and minimal cellular delineation in expansion and differentiation experiments. The company was founded by Dirk Groenewegen and Jan van der Hoeven in 2007 and is headquartered in Oss, the Netherlands. | - |
Jaeyong Bae | M | - |
Glycostem Therapeutics BV
Glycostem Therapeutics BV BiotechnologyHealth Technology Glycostem Therapeutics BV operates as a life science company which develops cellular immunotherapy and production technology platforms. It develops cellular immunotherapeutic for the treatment of leukemia, lymphomas, and other forms of cancer. The firm provides Prototype NK-cell and NK-cell progenitor cell products for clinical evaluations and intervention studies; and GBGM, a cell survival and minimal cellular delineation in expansion and differentiation experiments. The company was founded by Dirk Groenewegen and Jan van der Hoeven in 2007 and is headquartered in Oss, the Netherlands. | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Dirk Groenewegen | M | - |
Glycostem Therapeutics BV
Glycostem Therapeutics BV BiotechnologyHealth Technology Glycostem Therapeutics BV operates as a life science company which develops cellular immunotherapy and production technology platforms. It develops cellular immunotherapeutic for the treatment of leukemia, lymphomas, and other forms of cancer. The firm provides Prototype NK-cell and NK-cell progenitor cell products for clinical evaluations and intervention studies; and GBGM, a cell survival and minimal cellular delineation in expansion and differentiation experiments. The company was founded by Dirk Groenewegen and Jan van der Hoeven in 2007 and is headquartered in Oss, the Netherlands. | - |
Statistics
Country | Connections | % of total |
---|---|---|
Netherlands | 4 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Jan Spanholtz
- Personal Network